Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:FASEB J
Auteurs principaux: Kaftanovskaya, Elena M., Ng, Hooi Hooi, Soula, Mariluz, Rivas, Bryan, Myhr, Courtney, Ho, Brian A., Cervantes, Briana A., Shupe, Thomas D., Devarasetty, Mahesh, Hu, Xin, Xu, Xin, Patnaik, Samarjit, Wilson, Kenneth J., Barnaeva, Elena, Ferrer, Marc, Southall, Noel T., Marugan, Juan J., Bishop, Colin E., Agoulnik, Irina U., Agoulnik, Alexander I.
Format: Artigo
Langue:Inglês
Publié: Federation of American Societies for Experimental Biology 2019
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/
https://ncbi.nlm.nih.gov/pubmed/31419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires